FDA: New logic model sets structured approach to REMS development
Regulatory NewsJoanne S. Eglovitch
Adverse eventsCDERMarket withdrawalPharmaceuticalsPharmacovigilancePharmacovigilance/postmarket surveillanceRisk managementUnited StatesRegulatory NewsJoanne S. EglovitchAdverse eventsCDERMarket withdrawalPharmaceuticalsPharmacovigilancePharmacovigilance/postmarket surveillanceRisk managementUnited States